Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey
peer reviewed ; Objectives: We evaluated azacitidine (VidazaH) safety and efficacy in patients with myelodysplastic syndrome (MDS), acute myeloid leukaemia (AML), and chronic myelomonocytic leukaemia (CMML), in a real-life setting. Treatment response, dose, and schedule were assessed. Methods: This non-interventional, post-marketing survey included 49/50 patients receiving azacitidine at 14 Belgian haematology centres from 2010–2012. Treatment-emergent adverse events (TEAEs), including treatment-related TEAEs, and serious TEAEs (TESAEs) were recorded throughout the study. Treatment response [c... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | journal article |
Erscheinungsdatum: | 2015 |
Verlag/Hrsg.: |
Acta Clinica Belgica
|
Schlagwörter: | Azacitidine / Myelodysplastic syndromes / Acute myeloid leukaemia / Chronic myelomonocytic leukaemia / Human health sciences / Hematology / Sciences de la santé humaine / Hématologie |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26503612 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://orbi.uliege.be/handle/2268/177558 |